← Evidence map

ArticleAnnals of hematology2025

t(14;22)(q32;q11) translocation involving IGH and IGL acquired at progression of splenic marginal zone lymphoma treated with rituximab, ibrutinib, and obinutuzumab.

Julia T Geyer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

t(14;22)(q32;q11) translocation involving IGH and IGL acquired at progression of splenic marginal zone lymphoma treated with rituximab, ibrutinib, and obinutuzumab. | OpenQuestion